LHNVD-501
Prevention of bacterial infections and sepsis
Key Facts
About Longhorn Vaccines
Longhorn Vaccines & Diagnostics is a private, integrated biotech company with a dual focus on diagnostics and vaccine development. Its commercial foundation is built on PrimeStore MTM, a patented molecular transport medium that inactivates pathogens and preserves nucleic acids, which gained significant utility during the COVID-19 pandemic. The company's R&D pipeline is centered on a composite peptide vaccine platform, with lead candidate LHNVD-303 targeting sepsis from bacterial infections and antimicrobial-resistant tuberculosis, and LHNVD-501, a monoclonal antibody for preventing bacterial infections and sepsis. Longhorn operates as a small, agile organization leveraging over 35 years of collective biotech experience to address global public health threats.
View full company profile